94105-90-5
基本信息
(+)-雌马酚
R,S-雌马酚
纳米脂质体雌马酚
(卤)-EQUOL
雌马酚,(±)-雌马酚
雌马酚 98% 不是S型,混旋的
3-(4-羟基苯基)四氢苯并吡喃-7-醇
(+/-)Equol
(+/-)-EQUOL
Equol,99%e.e.
EQUOL(RACEMIC)
(+/-)-Equol>
(+/-)-Equol (GMP)
7,4'-HoMoisoflavane
(±)-EQUOL >= 99.0% (TLC)
4′,7-Dihydroxyisoflavane
物理化学性质
| 熔点 | 158-160?C |
| 沸点 | 441.7±45.0 °C(Predicted) |
| 密度 | 1.286±0.06 g/cm3(Predicted) |
| 储存条件 | -20°C冷冻 |
| 溶解度 | 溶于乙醇 |
| 酸度系数(pKa) | 9.94±0.40(Predicted) |
| 形态 | 结晶粉末 |
| 颜色 | 白色至浅黄色至浅红色 |
| 水溶解性 | Soluble in DMSO and methanol or 100% ethanol. Insoluble in water. |
| 敏感性 | 吸湿性 |
| BRN | 87752 |
| InChI | InChI=1S/C15H14O3/c16-13-4-1-10(2-5-13)12-7-11-3-6-14(17)8-15(11)18-9-12/h1-6,8,12,16-17H,7,9H2 |
| InChIKey | ADFCQWZHKCXPAJ-UHFFFAOYSA-N |
| SMILES | C1OC2=CC(O)=CC=C2CC1C1=CC=C(O)C=C1 |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H302-H315-H319-H332-H335 |
| 防范说明 | P261-P280-P305+P351+P338 |
| WGK Germany | 3 |
| 海关编码 | 2932990090 |
| 存储类别 | 11 - Combustible Solids |
制备方法
10499-17-9
531-95-3
在氮气保护下，将化合物3a（0.20 g，0.78 mmol）、n-Bu4NI（1.01 g，2.73 mmol）和无水CH2Cl2（5 mL）的混合物搅拌并冷却至-78℃。随后，向冷却的混合物中逐滴加入BCl3（1 M，2.73 mL，2.73 mmol）的CH2Cl2溶液。将反应混合物搅拌并在2小时内缓慢升温至0℃。反应完成后，用冰水（10 mL）小心淬灭，继续搅拌20分钟，然后用饱和NaHCO3溶液（10 mL）中和。真空浓缩后，用EtOAc（10 mL×0.5）萃取残余物。合并有机层，用无水MgSO4干燥。过滤后，滤液经真空浓缩，通过硅胶柱色谱（乙酸乙酯/正己烷=1:3）纯化，得到无色晶体雌马酚3b（0.18 g，收率95%）。雌马酚的性质如下：熔点162-164℃（文献值158℃）；薄层色谱Rf值0.24（乙酸乙酯/正己烷=1:3）；红外光谱（KBr）νmax：3231, 2897, 1598, 1510, 1470, 1366, 1252, 1158, 1119, 826 cm-1；1H-NMR（400 MHz, DMSO-d6）δ：2.80（m, 2H, H-3和H-4a），3.01（m, 1H, H-4b），3.89（t, J=10.4 Hz, 1H, H-2a），4.14（d, J=10.4 Hz, 1H, H-2b），6.20（d, J=2.4 Hz, 1H, H-8），6.29（dd, J=8.4, 2.4 Hz, 1H, H-6），6.72（d, J=8.4 Hz, 2H, H-3', H-5'），6.86（d, J=8.4 Hz, 1H, H-5），7.10（d, J=8.4 Hz, 2H, H-2', H-6'），9.18（s, 1H, OH），9.29（s, 1H, OH）；13C-NMR（100 MHz, DMSO-d6）δ：31.3, 37.2, 70.3, 102.5, 108.0, 112.6, 115.3, 128.3, 130.1, 131.7, 154.5, 156.2, 156.5；电子轰击质谱（70 eV）m/z（相对强度，百分比）：242（M+, 58），135（25），134（40），123（88），120（100），107（39），91（37）。元素分析计算值（C15H14O3）：C 74.36，H 5.82；实测值：C 74.13，H 5.90。
参考文献：
[1] Tetrahedron Letters, 2009, vol. 50, # 18, p. 2121 - 2123
[2] Patent: US2010/298581, 2010, A1. Location in patent: Page/Page column 7-8
[3] Bioorganic and Medicinal Chemistry, 2004, vol. 12, # 6, p. 1559 - 1567
雌马酚价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/09/15 | HY-100583AR | 雌马酚 (±)-Equol (Standard) | 94105-90-5 | 5 mg | 800元 |
| 2026/09/15 | HY-100583AR | 雌马酚 (±)-Equol (Standard) | 94105-90-5 | 10 mg | 1280元 |
| 2026/09/15 | HY-100583AR | 雌马酚 (±)-Equol (Standard) | 94105-90-5 | 25 mg | 2560元 |
常见问题列表
Equol is first isolated and identified from pregnant-mares' urine and later found in the urine of the goat, cow, hen and sheep. Equol, unlike the soy isoflavones daidzein or genistein, has a chiral center and therefore can occur as 2 distinct diastereoisomers. S-equol is the exclusive product of human intestinal bacterial synthesis from soy isoflavones and both enantiomers are bioavailable. S-equol has a high affinity for estrogen receptor beta (K i =0.73 nM), whereas R-equol is relatively inactive. Equol could promote the proliferation and differentiation of rat osteoblasts through activating the ER-PKCα-related signaling pathway. The alkaline phosphatase activity also increases significantly in all of the equol and 17β-estradiol (E2 ) groups. Equol also significantly elevates the osteocalcin levels.
Equol is a modest natriuretic and vasorelaxant agent in the rat. Orally administered equol is about 8-fold less potent than orally administered furosemide. In isolated aortic rings precontracted by administration of phenylephrine, administration of equol relaxes the contracted aorta (concentration for half-maximal activity 58.9±16 μM). Equol possesses anticancer activity that suppresses tumor formation via apoptosis induction in rats with DMBA-induced mammary gland tumors. In addition, equol shows a hepatic protective effect by acting as an antioxidant and by reducing apoptosis.